Timothy P. Noyes Sells 10,000 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Stock

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Timothy P. Noyes sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $24.70, for a total value of $247,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Timothy P. Noyes also recently made the following trade(s):

• On Monday, April 1st, Timothy P. Noyes sold 10,000 shares of Aerovate Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $300,000.00.

Aerovate Therapeutics Stock Performance

Shares of NASDAQ AVTE opened at $22.05 on Friday. The stock has a market cap of $614.31 million, a price-to-earnings ratio of -7.66 and a beta of 1.23. The business has a 50 day simple moving average of $24.44 and a 200 day simple moving average of $19.14. Aerovate Therapeutics, Inc. has a 52 week low of $9.41 and a 52 week high of $32.42.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Jefferies Financial Group assumed coverage on Aerovate Therapeutics in a research note on Monday, March 25th. They set a “buy” rating and a $65.00 target price on the stock. Wedbush reaffirmed an “outperform” rating on shares of Aerovate Therapeutics in a research note on Thursday, April 4th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $35.00 target price on shares of Aerovate Therapeutics in a research note on Monday, April 1st.

Institutional Investors Weigh In On Aerovate Therapeutics

Large investors have recently made changes to their positions in the company. UBS Group AG bought a new stake in shares of Aerovate Therapeutics in the 3rd quarter valued at approximately $26,000. Tower Research Capital LLC TRC grew its stake in shares of Aerovate Therapeutics by 136.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 2,702 shares of the company’s stock valued at $55,000 after buying an additional 1,558 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Aerovate Therapeutics by 318.0% in the 4th quarter. Legal & General Group Plc now owns 3,235 shares of the company’s stock valued at $95,000 after buying an additional 2,461 shares in the last quarter. Citigroup Inc. grew its stake in shares of Aerovate Therapeutics by 1,351.5% in the 2nd quarter. Citigroup Inc. now owns 3,324 shares of the company’s stock valued at $57,000 after buying an additional 3,095 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Aerovate Therapeutics by 148.2% in the 4th quarter. Royal Bank of Canada now owns 3,475 shares of the company’s stock valued at $79,000 after buying an additional 2,075 shares in the last quarter.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.